Cornercap Investment Counsel Inc. cut its stake in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 53.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,432 shares of the company's stock after selling 10,684 shares during the quarter. Cornercap Investment Counsel Inc.'s holdings in LivaNova were worth $496,000 at the end of the most recent reporting period.
Other hedge funds have also modified their holdings of the company. Arizona State Retirement System lifted its position in shares of LivaNova by 2.0% in the 2nd quarter. Arizona State Retirement System now owns 15,104 shares of the company's stock valued at $828,000 after acquiring an additional 299 shares in the last quarter. Atria Investments Inc raised its stake in LivaNova by 6.2% during the 3rd quarter. Atria Investments Inc now owns 5,653 shares of the company's stock valued at $297,000 after purchasing an additional 331 shares during the period. Fifth Third Bancorp lifted its holdings in shares of LivaNova by 97.1% in the second quarter. Fifth Third Bancorp now owns 674 shares of the company's stock valued at $37,000 after purchasing an additional 332 shares in the last quarter. Hexagon Capital Partners LLC boosted its position in shares of LivaNova by 117.8% in the second quarter. Hexagon Capital Partners LLC now owns 684 shares of the company's stock worth $37,000 after buying an additional 370 shares during the period. Finally, State of Alaska Department of Revenue grew its holdings in shares of LivaNova by 7.3% during the third quarter. State of Alaska Department of Revenue now owns 6,246 shares of the company's stock valued at $328,000 after buying an additional 425 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.
LivaNova Stock Down 0.4 %
NASDAQ:LIVN traded down $0.22 during trading hours on Friday, reaching $52.10. The company's stock had a trading volume of 357,203 shares, compared to its average volume of 546,838. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. The company has a market cap of $2.83 billion, a price-to-earnings ratio of 124.05 and a beta of 1.01. LivaNova PLC has a one year low of $42.75 and a one year high of $64.47. The business's 50-day moving average is $51.77 and its 200-day moving average is $52.93.
Wall Street Analyst Weigh In
Several brokerages recently issued reports on LIVN. Mizuho reduced their price objective on LivaNova from $80.00 to $70.00 and set an "outperform" rating for the company in a research note on Thursday, October 31st. Baird R W raised shares of LivaNova from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, September 17th. Stifel Nicolaus boosted their price objective on shares of LivaNova from $70.00 to $72.00 and gave the company a "buy" rating in a research report on Thursday, July 25th. StockNews.com downgraded shares of LivaNova from a "strong-buy" rating to a "buy" rating in a research report on Saturday. Finally, The Goldman Sachs Group began coverage on shares of LivaNova in a report on Friday, October 4th. They set a "buy" rating and a $65.00 price target on the stock. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, LivaNova has a consensus rating of "Buy" and a consensus target price of $69.17.
View Our Latest Report on LIVN
LivaNova Profile
(
Free Report)
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.
See Also
Before you consider LivaNova, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LivaNova wasn't on the list.
While LivaNova currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
